NeuroVigil, Inc., a company based in San Diego, has
announced that is has formed a multi-year alliance with a large Pharmaceutical
Company, which plans to deploy the iBrain technology in its pharmaceutical
The company also announced that it has separately created an
alliance with the University of Basel
, one of Europe's leading
biomedical research universities, to specifically tackle Rett Syndrome, a
lethal neurodevelopmental disorder that affects girls almost exclusively.
NeuroVigil's innovative proprietary suite of software
algorithms and portable brain activity monitors was launched commercially in
2009 and is now a prevailing model for early Central
Nervous System (CNS
The commercial agreement, five years in the making, is a
win-win partnership for both NeuroVigil and the pharmaceutical company as it
will greatly expand the latter's research and development capabilities by
gaining access to high-resolution and high-throughput data - automated analysis
of a variety of substances, including chemicals and genes - while augmenting
NeuroVigil's exclusive biomarker databases.
NeuroVigil will retain all rights to its data and any
biomarkers discovered by either party and will not advise the pharmaceutical
company on the pharmacological applications of its compounds.
Dr. Philip Low, Founder, Chairman, Chief Executive
Officer and Chief Scientific Officer of NeuroVigil notes that the uncapped
agreement is unrestricted and both parties remain free to collaborate with
other parties. "This new collaboration heralds an advancement for both
companies - to discover and promote innovative methods to monitor disease and
ultimately improve human health."